Supplementary Figure S5 from Fcγ Receptor Polymorphism in Patients with Relapsed/Refractory High-Risk Neuroblastoma Correlates with Outcomes in the SIOPEN Dinutuximab Beta Long-Term Infusion Trial

Supplementary Figure S5. Event-free survival and overall survival in HACA-positive and HACA-negative patients (A and B) and by dinutuximab beta exposure of above and below median AUC (C and D). AUC, area under the curve; EFS, event-free survival; HACA, human anti-chimeric antibodies; OS, overall survival; SE, standard error.